Department of Neurology, Yamagata Prefectural Central Hospital, Japan.
Department of Respiratory Medicine, Yamagata Prefectural Central Hospital, Japan.
Intern Med. 2021 Sep 15;60(18):3025-3029. doi: 10.2169/internalmedicine.6917-20. Epub 2021 Mar 29.
Dermatomyositis is a rare immune-related adverse event caused by immune checkpoint inhibitors. We herein report a 75-year-old Japanese man with small-cell lung carcinoma who developed dermatomyositis after the administration of atezolizumab. He developed rashes on day 13 and myalgia and motor weakness on day 30 of the first administration of atezolizumab. Anti-transcriptional intermediary factor 1-gamma antibody was positive, and serum interleukin-6 levels were prominently elevated in the acute phase. Symptoms were improved by corticosteroid therapy. This is the first report of dermatomyositis associated with atezolizumab. Clinicians should be aware of the possibility of dermatomyositis after the administration of immune checkpoint inhibitors.
皮肌炎是一种由免疫检查点抑制剂引起的罕见免疫相关不良反应。我们在此报告一例 75 岁日本男性小细胞肺癌患者，在接受阿替利珠单抗治疗后发生皮肌炎。他在接受阿替利珠单抗首次治疗的第 13 天出现皮疹，第 30 天出现肌痛和运动无力。抗转录中介因子 1-γ 抗体阳性，急性期血清白细胞介素-6 水平明显升高。皮质类固醇治疗后症状改善。这是首例与阿替利珠单抗相关的皮肌炎报告。临床医生应意识到免疫检查点抑制剂治疗后发生皮肌炎的可能性。
